ArticleFrontiers in pharmacology2026
Efficacy and safety of camrelizumab-based regimens in advanced squamous cell carcinoma patients: a prospective multicenter study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Camrelizumab-based regimens show promising efficacy in esophageal cancer patients, according to previous pivotal trials. Given the strict eligibility criteria in pivotal trials, real-world studies are essential to evaluate the efficacy and safety of camrelizumab-based regimens in a broader patient population under routine clinical practice. Therefore, this study aimed to explore the efficacy and safety of camrelizumab-based regimens for the treatment of advanced esophageal cancer patients in real world settings. Methods: A total of 192 advanced esophageal cancer patients receiving camrelizumab-based regimens were included in this study. The specific camrelizumab-based regimens were decided by the investigators according to the patients' physical condition. For efficacy assessment, treatment response and survival were assessed. For safety assessment, adverse events were collected. The median (range) follow-up duration was 7.2 (0.7-58.8) months. Results: Objective response rate and disease control rate were 18.8% and 84.4%, respectively. Camrelizumab-based regimens achieved the median [95% confidence interval progression-free survival (PFS) and overall survival (OS) of 6.8 (5.4-8.2) and 17.4 (12.8-21.9) months, respectively. Compared to patients receiving camrelizumab monotherapy, progression-free survival was prolonged in patients receiving camrelizumab combination therapy ( Conclusion: Camrelizumab shows satisfactory efficacy and safety in advanced esophageal cancer patients, and the camrelizumab combination regimens seem to bring prolonged PFS than its monotherapy. The real-world design reflects routine clinical practice, supporting the generalizability of these findings. However, potential confounders may exist and the broad range of follow-up durations may contribute to variability in survival data. Therefore, our results should be interpreted cautiously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.